BRISTOL-MYERS SQUIBB COMPANY Equity Securities, FV-NI
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Equity Securities, FV-NI of $325.00 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:EquitySecuritiesFvNi · last filed 2026-07-30
- 2026-06-30: Equity Securities, FV-NI $325.00M.
- 2026-03-31: Equity Securities, FV-NI $237.00M.
- 2025-12-31: Equity Securities, FV-NI $552.00M.
- 2025-09-30: Equity Securities, FV-NI $444.00M.
| Period end | Equity Securities, FV-NI |
|---|---|
| 2026-06-30 | $325.00M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $237.00M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $552.00M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $444.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $277.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $273.00M 10-Q · filed 2025-04-24 |
| 2024-12-31 | $289.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $688.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $593.00M 10-Q · filed 2024-07-26 |
| 2024-03-31 | $562.00M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $459.00M 10-K · filed 2025-02-12 |
| 2023-09-30 | $346.00M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $848.00M 10-Q · filed 2023-07-27 |
| 2023-03-31 | $907.00M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $1.10B 10-K · filed 2024-02-13 |
| 2022-09-30 | $919.00M 10-Q · filed 2022-10-26 |
| 2022-06-30 | $1.05B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $1.45B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $2.02B 10-K · filed 2023-02-14 |
| 2021-09-30 | $3.88B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $3.41B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $3.26B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $3.45B 10-K · filed 2022-02-09 |
| 2020-09-30 | $3.06B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.85B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.97B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $2.19B 10-K · filed 2021-02-10 |
| 2019-09-30 | $260.00M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $495.00M 10-Q · filed 2019-07-25 |
| 2019-03-31 | $436.00M 10-Q · filed 2019-04-25 |
| 2018-12-31 | $479.00M 10-K · filed 2020-02-24 |
| 2017-12-31 | $132.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |